Brief: Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder
13/05/2025 12:41
May 13 (Reuters) - ATAI LIFE SCIENCES ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF EMP-01 FOR THE TREATMENT OF SOCIAL ANXIETY DISORDER ATAI LIFE SCIENCES NV - TOPLINE DATA EXPECTED IN Q1 2026 Source text: ID:nGNX8tM0k3 ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AtaiBeckley
See all newsFDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM